Dameron Levest Jones

Array ( [id] => 20329706 [patent_doc_number] => 12459972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Protease-activated contrast agents for in vivo imaging [patent_app_type] => utility [patent_app_number] => 18/053682 [patent_app_country] => US [patent_app_date] => 2022-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 22 [patent_no_of_words] => 11402 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20163931 [patent_doc_number] => 20250255977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/706375 [patent_app_country] => US [patent_app_date] => 2022-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18706375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20927761 [patent_doc_number] => 12721914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-09-01 [patent_title] => Radiolabeled anti-LAG3 antibodies for immuno-PET imaging [patent_app_type] => utility [patent_app_number] => 18/049609 [patent_app_country] => US [patent_app_date] => 2022-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 29419 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18295832 [patent_doc_number] => 20230105518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => AN INJECTABLE AND IN-SITU CROSSLINKING HYDROGEL FOR ENDOVASCULAR EMBOLIZATION [patent_app_type] => utility [patent_app_number] => 17/952056 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17952056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067175 [patent_doc_number] => 20240101601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/945457 [patent_app_country] => US [patent_app_date] => 2022-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17945457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657067 [patent_doc_number] => 20240424132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/689166 [patent_app_country] => US [patent_app_date] => 2022-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18689166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091363 [patent_doc_number] => 20220409704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => Methods for Treating Cancer That Has A Phosphatidylinositol 3,4,5-Trisphosphate Rac Exchange Factor 2 (PREX2) Protein Expressed Thereon [patent_app_type] => utility [patent_app_number] => 17/929407 [patent_app_country] => US [patent_app_date] => 2022-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20341935 [patent_doc_number] => 12465651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Photodynamic therapy composition [patent_app_type] => utility [patent_app_number] => 17/901299 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 20 [patent_no_of_words] => 7132 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19830763 [patent_doc_number] => 20250082549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-13 [patent_title] => X-RAY OPAQUE FILLER MATERIAL, X-RAY OPAQUE DENTAL FILLER MATERIAL, METHOD FOR PRODUCING X-RAY OPAQUE FILLER MATERIAL, AND CURABLE DENTAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/580274 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18580274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401308 [patent_doc_number] => 12491268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Targeted protein contrast agents, methods of making, and uses thereof [patent_app_type] => utility [patent_app_number] => 17/819180 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 162 [patent_no_of_words] => 17196 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179516 [patent_doc_number] => 20230040245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/881350 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18198621 [patent_doc_number] => 20230052140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/876272 [patent_app_country] => US [patent_app_date] => 2022-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17876272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724453 [patent_doc_number] => 20230338612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => IN SITU FORMING COMPOSITE MATERIAL FOR TISSUE RESTORATION [patent_app_type] => utility [patent_app_number] => 17/873980 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17873980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034735 [patent_doc_number] => 20220378950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/811006 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430489 [patent_doc_number] => 20240298987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => Compounds For Molecular Imaging of Collagen Turnover and Methods Using Same [patent_app_type] => utility [patent_app_number] => 18/573604 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036194 [patent_doc_number] => 20220380409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS [patent_app_type] => utility [patent_app_number] => 17/844456 [patent_app_country] => US [patent_app_date] => 2022-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17844456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389943 [patent_doc_number] => 20230158161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/843796 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981132 [patent_doc_number] => 20220347168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => LUNG TARGETED ANTICANCER THERAPIES WITH LIPOSOMAL ANNAMYCIN [patent_app_type] => utility [patent_app_number] => 17/663133 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828563 [patent_doc_number] => 20220265867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/741686 [patent_app_country] => US [patent_app_date] => 2022-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836498 [patent_doc_number] => 20220273803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/739873 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739873 [rel_patent_id] =>[rel_patent_doc_number] =>)